A new biotech venture aiming to tackle aging at a genetic level, ARTAN Bio, has closed a $1.0M Seed funding round. The startup is focused on developing engineered tRNAs, a specialized class of molecules designed to suppress specific mutations that are directly associated with the aging process.
This initial capital infusion underscores a growing interest in innovative approaches to age-related conditions, providing ARTAN Bio with resources to advance its foundational research.













